Get the Stockscreener App
92.30
6.69%
5.79
After Hours:
92.30
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $92.30, with a volume of 2.08M.
It is up +6.69% in the last 24 hours and up +3.78% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$86.51
Open:
$89.16
24h Volume:
2.08M
Relative Volume:
1.72
Market Cap:
$10.32B
Revenue:
$2.86B
Net Income/Loss:
$239.88M
P/E Ratio:
44.16
EPS:
2.0903
Net Cash Flow:
$506.94M
1W Performance:
+8.36%
1M Performance:
+3.78%
6M Performance:
-0.29%
1Y Performance:
-0.57%
1-Day Range:
$87.04
$93.83
1-Week Range:
$81.22
$93.83
52-Week Range:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
92.30 | 9.67B | 2.86B | 239.88M | 506.94M | 2.0903 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity Earnings Call: Margin Beat, Portfolio Reset - TipRanks
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Outperforms in Q1 2026 Driven by Pharma Rebound and Strategic Portfolio Shifts - Lab Manager
Revvity Q1 2026 earnings preview - MSN
Revvity Q1 2026 Earnings Call Transcript - MarketBeat
Revvity, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Revvity outlines 3%-4% 2026 organic growth and $5.20-$5.30 EPS while planning China immunodiagnostics divestiture - MSN
Revvity stock gains after beating first-quarter profit estimates By Investing.com - Investing.com India
Revvity stock gains after beating first-quarter profit estimates - Investing.com
Why Is Revvity (RVTY) Stock Rocketing Higher Today - TradingView
Revvity Releases Q1 2026 Financial Results - AlphaStreet
Revvity, Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:RVTY) 2026-05-05 - Seeking Alpha
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution - Yahoo Finance Singapore
Revvity Q1 2026 slides: revenue beats amid margin pressure, China exit - Investing.com Australia
Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Revvity Announces Financial Results for the First Quarter of 2026 - PharmiWeb.com
Revvity trims annual profit, sales forecast to exclude China immunodiagnostics unit - TradingView
Earnings call transcript: Revvity Q1 2026 shows strong earnings beat By Investing.com - Investing.com Canada
Earnings call transcript: Revvity Q1 2026 shows strong earnings beat - Investing.com
Revvity Q1 Earnings Call Highlights - Yahoo Finance
Revvity, Inc. Reports Earnings Results for the First Quarter Ended April 05, 2026 - marketscreener.com
Revvity (NYSE:RVTY) Beats Q1 CY2026 Sales Expectations - TradingView
Revvity (RVTY) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Revvity (NYSE:RVTY) Q1 2026 Earnings Beat Sends Shares Higher Despite Revenue Miss - ChartMill
Revvity Posts Strong Q1 Results and Updates 2026 Outlook - TipRanks
Revvity Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
REVVITY ($RVTY) Releases Q1 2026 Earnings - Quiver Quantitative
Revvity (NYSE: RVTY) posts Q1 growth, plans China diagnostics sale - Stock Titan
Revvity declares $0.07 dividend - MSN
Revvity: Q1 Earnings Snapshot - 10TV
Earnings Flash (RVTY) Revvity, Inc. Reports Q1 Revenue $711.1M, vs. FactSet Est of $704.2M - marketscreener.com
Earnings Flash (RVTY) Revvity, Inc. Posts Q1 Adjusted EPS $1.04 per Share, vs. FactSet Est of $1.02 - marketscreener.com
(RVTY) Revvity Expects 2026 Adjusted EPS Range $5.20-$5.30, vs. FactSet Est of $5.39 - marketscreener.com
(RVTY) Revvity Expects 2026 Pro Forma Revenue Range $2.81B-$2.84B - marketscreener.com
Revvity (NYSE:RVTY) Surprises With Q1 CY2026 Sales - TradingView
Revvity : First Quarter 2026 Non-GAAP Reconciliations - marketscreener.com
Earnings Flash (RVTY) Revvity, Inc. Posts Q1 Adjusted EPS $1.04 per Share, Vs. FactSet Est of $1.02 - Moomoo
Revvity Q1 Revenue USD 711.118 Million Vs. IB - Moomoo
Revvity earnings in focus as analysts eye revenue growth path - Investing.com
Baird Adjusts Revvity Price Target to $125 From $129, Maintains Outperform Rating - marketscreener.com
RVTY Maintains by Baird -- Price Target Lowered to $125 - GuruFocus
MSN Money - MSN
Revvity Earnings: What To Look For From RVTY - Yahoo Finance UK
Revvity to Report Q1 Earnings: What's in Store for the Stock? - Yahoo Finance
(RVTY) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Revvity, Inc. (RVTY) Stock Analysis: Healthcare Innovator With A 31.44% Upside Potential - DirectorsTalk Interviews
Revvity Stock Sinks as Cautious Outlook Spooks Wall Street - TipRanks
Revvity Shareholders Re-Elect Board, Approve Bylaw Change; Exec Stock Retention Proposal Fails - Yahoo Finance
Revvity to Hold Earnings Call on Tuesday, May 5, 2026 - Quantisnow
Revvity Board Declares Quarterly Dividend - The National Law Review
Bretton Capital Management, LLC's Revvity Inc(RVTY) Holding History - GuruFocus
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):